

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in





www.rockland.com tech@rockland.com +1 484.791.3823

Datasheet for R617-0100 Swine Buffy Coat Preparation

Overview

Description:	Swine Buffy Coat Preparation - R617-0100
Item No.:	R617-0100
Size:	100 μL
Origin:	Swine

Product Details

Background: Blood is a complex mixture of cells, proteins, metabolites and many other substances. About

56% of human blood volume is comprised of cells, more than 99% of which are erythrocytes. Human erythrocytes and thrombocytes (platelets, 0.5% blood components) do not contain nuclei. Leukocytes (0.3% of blood components), also referred to as peripheral blood mononuclear leukocytes or PBMC, do contain nuclei. Blood samples may vary widely in leukocyte (granulocytes, lymphocytes and monocytes) concentration depending on the health of the donor. Healthy blood contains less than 10E7 leukocytes per ml, while blood from an infected donor may have ten fold higher leukocyte concentrations. Buffy coat preparations are

useful for researchers interested in immunology and infectious disease research.

Synonyms: Swine Buffy Coat Preparation

Species of Origin: Swine

Target Details

Purity/Specificity: Buffy coat preparations are composed of leukocytes, trace amounts of red blood cells and other

components. Buffy coat preparations are separated after a single low-speed centrifugation to remove the platelet rich plasma, buffy coat layer and erythrocytes (RBC). If desired, you may further purify this preparation of leukocytes by sedimentation using Percoll™ gradient

centrifugation.

Application Details

Application Note: Buffy coat preparations are suitable for use as a source of nucleated PBMC. Buffy coat

preparations are separated after a single low-speed centrifugation to remove the platelet rich plasma, buffy coat layer and erythrocytes (RBC). Buffy coat preparations are generally enriched

www.rockland.com Page 1 of 3





www.rockland.com tech@rockland.com +1 484.791.3823

4.2mg/ml Sodium Chloride, 8.0 mg/ml Citric Acid Tri-sodium, adjusted to pH 6.1.
gradient centrifugation. This product is prepared in a buffer composed of 20.5 mg/ml Dextrose,
desired, you may further purify this preparation of leukocytes by sedimentation using Percoll™
for leukocytes (WBC) and contain trace amounts of red cells and other blood components. If

Assay Dilutions: All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.

Formulation

Physical State:	Frozen Cell Pellet
Buffer:	See application note.
Sterility:	Non-sterile

Shipping & Handling

Shipping Condition:	Dry Ice
Storage Condition:	Store vial at -70° C or COLDER. For extended storage, aliquot contents to minimize freeze/thaw cycles.
Expiration:	Expiration date is one (1) year from date of receipt.

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.

www.rockland.com Page 2 of 3





www.rockland.com tech@rockland.com +1 484.791.3823

www.rockland.com Page 3 of 3